{
  "report_rows": [
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$25.5B vs. cons $25.14-25.18B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "TREMFYA WW Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1.90B vs. cons $1.85B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "ICOTYDE Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$80-90M vs. cons ~$44M",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Operational Sales (FY2026)",
      "prediction": "BETTER",
      "answer": "guide ~$100.6-100.8B mid vs. cons $100.5B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Adj. Operational EPS (FY2026)",
      "prediction": "BETTER",
      "answer": "guide ~$11.45-11.55 mid vs. cons $11.58",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "ICOTYDE Qualitative Trajectory (FY2026)",
      "prediction": "BETTER",
      "answer": "More confident tone on prescriber ramp and payer coverage vs. Q1 early-stage language",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": -1.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 2.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 sell-the-news D1 reverses as analysts update models for raised FY guide; H2 implied math is clean with no implicit cut",
  "day5_confidence": "MEDIUM"
}